Intervention: Vancomycin
Trial phase: Phase 3
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 286
Group description: 125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
Eligibility criteria:
To be included in this study, participants must:

Sign a consent form;
Be >= 18 and < 90 years of age;
Have diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device;
Test positive for Clostridium difficile;
If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study.

Participants will not be allowed into the study if they:

Have toxic megacolon and/or known small bowel ileus;
Have received treatment with intravenous immune globulin (IVIG) within the past 30 days;
Have received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study;
Have received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working;
Have received an investigational vaccine against C. difficile;
Have received an investigational product containing monoclonal antibodies against toxin A or B within 180 days;
Had more than 2 episodes of CDAD within 90 days;
Had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months (this does not include appendectomy or cholecystectomy);
Have history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis;
Are unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study;
Are unable to discontinue opiate treatment unless on a stable dose;
Has known positive stool cultures for other enteropathogens including but not limited to Salmonella, Shigella, and Campylobacter;
Had stool studies positive for pathogenic ova and/or parasites;
Have an intolerance or hypersensitivity to daptomycin and/or vancomycin;
Have life-threatening illness at the time of enrollment;
Have poor concurrent medical risks that in the opinion of the Investigator the participant should not enroll;
Have received an investigational drug or participated in any experimental procedure within 1 month;
Have human immunodeficiency virus (HIV), a cluster of differentiation 4 (CD4) < 200 cells/mm3 within 6 months of start of study therapy;
Anticipate that certain antibacterial therapy for a non-CDAD infection will be required for > 7 days;
Are unable to discontinue Saccharomyces or similar probiotic;
Are on a concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy;
Are unable to comply with the protocol requirements;
Have any condition that, in the opinion of the Investigator, might interfere;
Are not expected to live for less than 8 weeks.